Molecular Imaging Agents for Vulnerable Plaque Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques are unable to effectively distinguish vulnerable atherosclerotic plaques from stable ones, as they primarily rely on structural abnormalities and require invasive endovascular access, failing to characterize biological plaque activity and predict rupture risk.
Innovation Solution
Development of specific molecular imaging agents comprising peptides or antibodies that bind selectively to myeloperoxidase, allowing for non-invasive identification of vulnerable plaques using detectable labels for imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current imaging techniques are used to detect atherosclerotic plaques, then structural abnormalities can be visualized, but vulnerable plaques cannot be selectively identified and rupture risk cannot be predicted
Solution Approach 1:
The patent employs molecular imaging agents as intermediaries that selectively bind to myeloperoxidase, a marker protein found in vulnerable plaques. These agents serve as mediators between the imaging system and the biological target, enabling detection of plaque vulnerability through specific molecular interactions rather than relying solely on structural abnormalities.
Solution Approach 2:
The invention transitions from detecting plaques based on structural parameters (luminal narrowing, plaque size) to detecting based on biological parameters (myeloperoxidase expression, inflammatory activity). This parameter change enables differentiation between vulnerable and stable plaques, providing information about plaque rupture risk that was previously unavailable.
2Measurement precision
If invasive endovascular approaches are used to identify vulnerable plaques, then direct visualization can be achieved, but patient risk and procedural complexity increase
Solution Approach 1:
The patent replaces invasive mechanical endovascular approaches with non-invasive molecular imaging techniques. Instead of using catheters and contrast agents to directly visualize plaques through mechanical means, the system uses radiolabeled molecular agents that accumulate in vulnerable plaques and are detected through imaging, thereby eliminating the associated invasive risks.
Solution Approach 2:
Molecular imaging agents act as safe intermediaries that can be administered non-invasively and selectively accumulate in vulnerable plaques. These agents provide the necessary diagnostic information without requiring direct access to the coronary arteries, thus eliminating the harmful effects of invasive procedures while maintaining detection accuracy.
3Object-affected harmful factors
If non-invasive imaging techniques are used, then patient safety is improved, but the ability to characterize biological plaque activity and predict rupture is lost
Solution Approach 1:
The invention enables non-invasive detection of biological plaque activity by changing the detection parameter from structural to molecular. By using molecular imaging agents that bind to myeloperoxidase, the system can non-invasively measure biological parameters such as inflammatory activity and plaque vulnerability, thereby preserving critical information about plaque rupture risk while maintaining patient safety.
Solution Approach 2:
The patent substitutes mechanical imaging approaches with molecular imaging mechanisms. Instead of relying on mechanical contrast enhancement or structural visualization that cannot detect biological activity, the system uses radiolabeled molecular agents that specifically interact with myeloperoxidase, enabling non-invasive characterization of plaque biology and rupture prediction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the selective identification and visualization of vulnerable plaques, potentially reducing morbidity and mortality by predicting plaque rupture and distinguishing them from stable plaques without invasive procedures.
Implementation Method 1
specific molecular imaging agents comprising a binding partner linked to a detectable label that can be used in vivo to visualize vulnerable plaques
Data Source
AI summary
The present invention provides compositions suitable for use as biomarkers of vulnerable plaques as well as methods for the use of such compositions. In preferred embodiments, specific molecular imaging agents are provided that permit the selective identification of vulnerable plaques in coronary and other arteries using non-invasive imaging methods. Such specific molecular imaging agents comprise a binding partner linked to a detectable label that can be used in vivo to visualize vulnerable plaques. In certain preferred embodiments, the binding partner is a peptide that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is an antibody that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is a portion of a polypeptide displayed by a bacteriophage that binds selectively to a component of a vulnerable plaque. In preferred embodiments, the component of a vulnerable plaque is myeloperoxidase or a portion thereof.